Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 51

Sort by

Sort Order Select

Journal Articles

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Eugenio Gaudio, PhD, Chiara Tarantelli, PhD, Luciano Cascione, PhD, Filippo Spriano, Gaetanina Golino, PhD, Lorenzo Scalise, Emanuele Zucca, MD, Anastasios Stathis, MD, Patrick H Van Berkel, PhD, Francesca Zammarchi, PhD, Francesco Bertoni, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-134664

Published: 2020

Journal Articles

Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142000

Published: 2020

Journal Articles

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Blood (2019) 134 (Supplement_1): 487.

https://doi.org/10.1182/blood-2019-122298

Published: 2019

Journal Articles

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Blood (2019) 134 (Supplement_1): 353.

https://doi.org/10.1182/blood-2019-129835

Published: 2019

Journal Articles

Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)

Juan Pablo Alderuccio, MD, Isildinha M Reis, PhD, Thomas M. Habermann, MD, Brian K. Link, MD, Catherine Thieblemont, MD PhD, Annarita Conconi, MD, Melissa C Larson, MS, Luciano Cascione, PhD, Wei Zhao, MD MS, James R. Cerhan, MD PhD, Emanuele Zucca, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 4010.

https://doi.org/10.1182/blood-2019-125008

Published: 2019

Journal Articles

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Alberto J Arribas, Sara Napoli, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Alessandra Di Veroli, Chiara Tarantelli, PhD, Filippo Spriano, Antonella Zucchetto, Francesca Maria Rossi, PhD, Andrea Rinaldi, Anastasios Stathis, MD, Georg Stuessi, MD, Valter Gattei, MD, Gabriele Cruciani, Emanuele Zucca, MD, Davide Rossi, MD PhD, Francesco Bertoni, MD

Blood (2019) 134 (Supplement_1): 2569.

https://doi.org/10.1182/blood-2019-124299

Published: 2019

Journal Articles

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Sara Alonso, MD, Martina Manni, PhD, Clementine Sarkozy, MD, Marielle Wondergem, MD, Attilio Guarini, MD, Laura Magnano, MD, Miguel Alcoceba, PhD, Martine E.D. Chamuleau, MD, Sara Galimberti, Maria Gomes da Silva, MD, Harald Holte, MD PhD, Emanuele Zucca, MD, Silvia Montoto, MD, Sandra Lockmer, MD, Igor Aurer, MD PhD, Luigi Marcheselli, MSc, Dolores Caballero, MD, Gilles Salles, MD PhD, Massimo Federico, MD

Blood (2018) 132 (Supplement 1): 4145.

https://doi.org/10.1182/blood-2018-99-115956

Published: 2018

Journal Articles

Plasma Cell Disease Genotyping with the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 327.

https://doi.org/10.1182/blood.V130.Suppl_1.327.327

Published: 2017

Journal Articles

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

Blood (2017) 130 (Supplement 1): 4062.

https://doi.org/10.1182/blood.V130.Suppl_1.4062.4062

Published: 2017

Journal Articles

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Elaine Y Chung, PhD, Filippo Spriano, Ivo Kwee, PhD, Sara Napoli, Chiara Tarantelli, PhD, Eugenio Gaudio, PhD, Luciano Cascione, PhD, Andrea Cavalli, Alberto Arribas, PhD, Andrea Rinaldi, Davide Rossi, MD PhD, Emanuele Zucca, MD, Anastasios Stathis, MD, Katti Jessen, PhD, Brian J Lannutti, PhD, Jeffrey Toretsky, MD, Francesco Bertoni, MD

Blood (2017) 130 (Supplement 1): 2810.

https://doi.org/10.1182/blood.V130.Suppl_1.2810.2810

Published: 2017

Journal Articles

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

Blood (2017) 130 (Supplement 1): 307.

https://doi.org/10.1182/blood.V130.Suppl_1.307.307

Published: 2017

Journal Articles

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Blood (2017) 130 (Supplement 1): 1506.

https://doi.org/10.1182/blood.V130.Suppl_1.1506.1506

Published: 2017

Journal Articles

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

Blood (2014) 124 (21): 799.

https://doi.org/10.1182/blood.V124.21.799.799

Published: 2014

Journal Articles

The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma

Elena Bernasconi, B.Sc., Chiara Tarantelli, Eugenio Gaudio, PhD, Ivo Kwee, Andrea Rinaldi, Luciano Cascione, Anastasios Stathis, MD, Maria Eugenia Riveiro, MD PhD, Emanuele Zucca, MD, Francesco Bertoni

Blood (2014) 124 (21): 3113.

https://doi.org/10.1182/blood.V124.21.3113.3113

Published: 2014

Journal Articles

BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma

Luciano Cascione, Eugenio Gaudio, PhD, Elena Bernasconi, B.Sc., Chiara Tarantelli, Andrea Rinaldi, Monica Testoni, B.Sc., Riccardo Bomben, Valter Gattei, Ivo Kwee, PhD, Anastasios Stathis, MD, Maria Eugenia Riveiro, MD PhD, Emanuele Zucca, MD, Francesco Bertoni

Blood (2014) 124 (21): 4495.

https://doi.org/10.1182/blood.V124.21.4495.4495

Published: 2014

Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

Catherine Thieblemont, MD PhD, Anastasios Stathis, MD, Giorgio Inghirami, MD, Lionel Karlin, Franck Morschhauser, MD PhD, Mary Gleeson, FRCPath, Florence Broussais, MD, Sandy Amorim, MD, Gilles Salles, MDPhD, Thierry Facon, MD, David Cunningham, FMedSci, Norbert Vey, MD PhD, Fabrice Bourdel, MSc, Patrice Herait, MD, Emanuele Zucca, MD

Blood (2014) 124 (21): 4417.

https://doi.org/10.1182/blood.V124.21.4417.4417

Published: 2014

Journal Articles

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Anastasios Stathis, MD, Arnold S. Freedman, MD, Ian W. Flinn, MD, Kami J. Maddocks, MD, Steven Weitman, MDPhD, Jesus G. Berdeja, MD, Alex V. Mejia, MD, Emanuele Zucca, MD, Rebecca Green, Angela Romanelli, PhD, Sybil H Zildjian, MPH, Rodrigo Ruiz-Soto, MD MSc, Lia Palomba, MD

Blood (2014) 124 (21): 1760.

https://doi.org/10.1182/blood.V124.21.1760.1760

Published: 2014

Journal Articles

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren’s Disease and May Not Benefit from Local Therapy

Amie E Jackson, MD, Michael Mian, Christina H. Kalpadakis, MD, Gerassimos A Pangalis, MD, Anastasios Stathis, MD, Elena Porro, MSc, Ellen D McPhail, MD, Thomas M Habermann, MD, Kay M. Ristow, Franco Cavalli, MD, Grzegorz S. Nowakowski, MD, Emanuele Zucca, MD

Blood (2014) 124 (21): 1637.

https://doi.org/10.1182/blood.V124.21.1637.1637

Published: 2014

Journal Articles

The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

Chiara Tarantelli, Eugenio Gaudio, PhD, Ivo Kwee, PhD, Andrea Rinaldi, Matteo Stifanelli, Elena Bernasconi, B.Sc., Chiara Barassi, Petra Hillmann, Anastasios Stathis, MD, Laura Carrassa, Massimo Broggini, Georg Stussi, MD, Doriano Fabbro, Paul Hebeisen, Frances Betts, Andreas Wicki, Emanuele Zucca, MD, Vladimir Cmiljanovic, Francesco Bertoni

Blood (2014) 124 (21): 1782.

https://doi.org/10.1182/blood.V124.21.1782.1782

Published: 2014

Journal Articles

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

Isabelle Fleury, MD, Sylvie Chevret, MD PhD, Michael Pfreundschuh, Gilles Salles, MDPhD, Bertrand Coiffier, MD PhD, Marinus H.J. van Oers, Christian Gisselbrecht, MDPhD, Emanuele Zucca, MD, Michael Herold, MDPhD, Michele Ghielmini, MD, Catherine Thieblemont, MDPhD

Blood (2014) 124 (21): 1659.

https://doi.org/10.1182/blood.V124.21.1659.1659

Published: 2014

NARROW

Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identification of Potential Biomarkers for Its Activity

Evaluation of the Different Stratification Models for POD24 Prediction in Patients with Follicular Lymphoma

The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma: An Individual Patient Data Meta-Analysis By the Petra Consortium

Sequential Matrix-RICE Therapy Followed By Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma and Secondary Central Nervous System Involvement: The International Extranodal Lymphoma Study Group-42 Phase II (MARIETTA) Trial

Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)

Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance

Risk of Histological Transformation in Patients with Primary Refractory Follicular Lymphoma

Plasma Cell Disease Genotyping with the Liquid Biopsy

Bendamustine in Combination with Rituximab As First-Line Treatment of Splenic Marginal Zone Lymphoma (BRISMA). Results of the IELSG-36 Phase II Study

The ETS Inhibitors Yk-4-279 and TK-216 Interfere with Spib and Synergize with Lenalidomide in Diffuse Large B Cell Lymphoma of the Activated B Cell-like Type (ABC DLBCL)

Genotyping of Classical Hodgkin Lymphoma on the Liquid Biopsy

IELSG-38: A Phase II Study of Chlorambucil in Combination with Rituximab Followed By Maintenance Therapy with Subcutaneous Rituximab in Patients with Extranodal Marginal Zone B-Cell Lymphoma of Mucosa Associated Lymphoid Tissue (MALT)

Rituximab Plus Lenalidomide Improves the Complete Remission Rate in Comparison with Rituximab Monotherapy in Untreated Follicular Lymphoma Patients in Need of Therapy. Primary Endpoint Analysis of the Randomized Phase-2 Trial SAKK 35/10

The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma

BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrornas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Non-Leukemic Hematologic Malignancies

A Phase I Study of IMGN529, an Antibody-Drug Conjugate (ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma (NHL)

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) of the Salivary Gland Is Associated with Improved Prognosis When Arising in a Background of Sjögren’s Disease and May Not Benefit from Local Therapy

The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response

No Increased Risk of Secondary Neoplasms in Patients Treated with Rituximab for Non-Hodgkin’s Lymphoma : A Meta-Analysis of 9 Trials

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only